Novo Nordisk’s amylin obesity drug keeps performing like Zepbound

statnews.com/2025/06/22/novo-nordisk-cagrisema-weight-loss-drug-comparison-eli-lilly-zepbound-investors-disappointed

CHICAGO — Late-stage results of Novo Nordisk’s obesity candidate CagriSema suggest the drug is comparable to Eli Lilly’s Zepbound on safety and efficacy, further data indicating that CagriSema may not be the standout treatment that investors had hoped for.
Novo previously reported that…

This story appeared on statnews.com, 2025-06-22 19:55:19.670000.
The Entire Business World on a Single Page. Free to Use →